Acacia Research Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless stated otherwise. Acacia operates in intellectual property licensing and enforcement, industrial printing through Printronix, and energy through Benchmark. Benchmark was acquired in November 2023, so its results are included in the current period but not the prior-year comparison.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $24.3 million | $14.8 million; up 64% |
| Operating loss | $2.1 million | $9.3 million loss |
| Net income (loss) attributable to Acacia | $(0.2) million | $9.4 million income |
| Operating margin | (8.6%) | (63.0%) |
| Cash from operating activities | $54.8 million | $4.3 million used |
| Cash and cash equivalents, March 31 | $438.8 million | $340.1 million at December 31, 2023 |
| Total assets / total liabilities, March 31 | $631.7 million / $42.1 million | $633.5 million / $43.9 million at December 31, 2023 |
| Revolver borrowings, March 31 | $13.0 million | $10.5 million at December 31, 2023; 11% interest rate |
Revenue growth was led by intellectual property operations, which generated $13.6 million versus $4.2 million. Industrial operations revenue declined to $8.8 million from $10.6 million, mainly due to fewer printer units sold. Energy operations contributed $1.9 million in its first reported Q1. Segment operating income was $3.3 million for intellectual property, $1.2 million for industrial, and $0.2 million for energy; parent-company general and administrative expense of $6.7 million drove the consolidated operating loss.
Cash generation benefited substantially from $77.5 million of intellectual-property customer receipts and a $65.2 million reduction in accounts receivable. Investing activities provided $42.0 million, mainly reflecting securities sales, including Arix shares; financing activities provided $1.8 million. Cash, cash equivalents, and equity securities totaled $461.7 million at quarter-end. The filing reports basic and diluted loss per share as “—”; it does not provide a clear numerical per-share loss.
Material changes and unusual items
- On January 19, 2024, Acacia completed the sale of its Arix Bioscience shares for $57.1 million. The sale contributed to a $28.9 million realized securities gain, alongside a $26.7 million unrealized securities loss; together, net realized and unrealized gains were $2.2 million.
- Acacia recorded a further $6.2 million expense in Q1 for the AIP legal matter involving former executives’ profit interests. The related accrued loss contingency was $8.5 million at March 31, including $2.3 million expensed in earlier periods.
- Intellectual-property revenue increased with six new license agreements, compared with four a year earlier. The filing says licensing revenue is uneven and identifies no pending patent-infringement case with a scheduled trial date in the next 12 months; it also reports no new patent portfolios acquired in Q1.
- Q1 2023 earnings included a $16.7 million fair-value gain on Series B warrants and embedded derivatives, and $0.9 million of interest expense on Senior Secured Notes. Those instruments and notes were no longer outstanding in Q1 2024 after 2023 recapitalization transactions.
- Subsequent event: On April 17, 2024, Benchmark acquired additional Texas and Oklahoma assets for $145 million, subject to customary adjustments. Acacia contributed $59.9 million from cash; the remainder was funded with new-facility borrowings and an investor contribution. Acacia’s Benchmark ownership increased from 50.4% to approximately 73.5%. At closing, $82.7 million, including $0.66 million of letters of credit, was drawn under a new facility with a $150 million maximum aggregate credit amount.
Outlook, liquidity, and risks
Management said cash and cash-equivalent balances and operating cash flows should be sufficient to meet cash requirements for at least 12 months from the filing date. Acacia intends to pursue further acquisitions and may use cash, debt, or equity financing; it provided no specific earnings or revenue guidance. Management cautions that intellectual-property revenue can fluctuate materially, patent-related legal expenses vary, and acquisitions may not be completed or deliver expected benefits.
Key risks include the AIP matter and other litigation, patent validity and enforcement outcomes, volatility in equity-investment values, and Benchmark’s exposure to commodity prices, production, reserve replacement, hedging, environmental obligations, and debt covenants. Benchmark was reported in compliance with its existing revolver covenants at March 31. Acacia’s controlling shareholder, Starboard Value, held approximately 61.2% of common stock as of May 6, 2024. The company reported effective disclosure controls and no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the April Benchmark acquisition and new borrowing produce the expected operating cash flow, leverage, and covenant headroom; the post-acquisition facility is secured by substantially all Benchmark assets.
- The amount, timing, and eventual resolution of the AIP contingency, and any developments in the Slingshot patent-portfolio litigation.
- Whether Q1 intellectual-property licensing strength is repeatable, given the company’s disclosure of uneven results and no new patent-portfolio acquisitions in Q1.
- The composition and valuation sensitivity of remaining equity investments; the filing estimates a 10% adverse market-price move in publicly traded holdings would reduce their value by about $2.3 million.
- The per-share loss figure, which is displayed as a dash in the filing’s statements rather than a clear numerical amount.